Immunowake

Immunowake is a biotech startup based in Shanghai, China, and Birmingham, AL, that operates in the pharmaceutical industry. The company specializes in the development of multi-target therapeutics, focusing on the use of PD-L1 antibodies. PD-L1 antibodies are a type of drug used in cancer treatment that helps the immune system recognize and attack cancer cells.

Immunowake's business model revolves around research, development, and commercialization of its portfolio of therapeutics. The company has secured exclusive licenses for the use of PD-L1 antibodies from Genescience Pharmaceuticals Co., Ltd and Genscript Biotech Corp. The specifics of these agreements have not been disclosed, but they provide Immunowake with a unique advantage in the market.

The company serves a broad range of clients, primarily within the healthcare sector. These include hospitals, clinics, and other healthcare providers, as well as patients who require cancer treatment.

Immunowake generates revenue through the sale of its therapeutics to these healthcare providers. The company has successfully raised significant funding to support its operations and growth. In 2019, it raised $3M in financing, led by Changchun High-tech Industries Group Inc. More recently, in May 2022, Immunowake raised $20M in pre-series A financing from investors including Hyfinity Investments, South China Venture, Lapam Capital, and HEDA Ventures. This funding will be used to accelerate the company's research, development, and commercialization efforts.

Keywords: Biotech, Pharmaceuticals, PD-L1 Antibodies, Cancer Treatment, Research and Development, Commercialization, Healthcare Providers, Financing, Pre-Series A, Exclusive Licenses.